Literature DB >> 8180337

A new variant of interaction between phospholipid antibodies and the protein C system.

M I Bokarewa1, M Blombäck, N Egberg, S Rosén.   

Abstract

The influence of 38 IgG fractions with either cardiolipin antibodies only (CLa) or both CLa and lupus anticoagulant activity (LA) on the response to activated protein C (APC) and on the snake venom activation of protein C were investigated. Five of eight IgG fractions with LA activity showed a tendency to reduce the effect of APC in the aPTT method and to simulate the APC-resistance phenomenon. This effect was not observed in IgG fractions without LA activity. The addition of IgG fractions did not decrease enzymatic activation of protein C in normal plasma. No correlation was found between sample protein C activity and CLa level or the extent of clotting time prolongation. These observations suggested that acquired resistance to APC in the presence of some types of phospholipid antibodies may be a cause of thrombophilia in such patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8180337     DOI: 10.1097/00001721-199402000-00006

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  4 in total

1.  Multiple myeloma presenting as mesenteric venous thrombosis and intestinal infarction.

Authors:  Darren A Kastin; John Andrews; Rohit Shah; David Green; John Fryer; Alan L Buchman
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

2.  Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro.

Authors:  D A Tsakiris; M L Yasikoff; F Wolf; G A Marbet
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

3.  Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies.

Authors:  Omid Safa; Charles T Esmon; Naomi L Esmon
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

4.  On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies.

Authors:  M D Smirnov; D T Triplett; P C Comp; N L Esmon; C T Esmon
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.